What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 24 months?
One-OffGezondheid en geneeskundeWetenschap1mnd
Manifold MarketsGeen KYCGeverifieerde afwikkelingsgegevensRedelijk gekalibreerdWaarschuwing datakwaliteitBrongegevens verslechterd
Gegevens van 26 okt 2026, 14:34 UTC · beleid pm-quality-4
Huidige gemeenschapsvoorspelling70-79% 38.7%Koploper van 7 uitkomsten
Voorspellers
14
Vraagtype
multiple choice
Methodologie
Play-money forecasting platform
Brontype
Voorspelling
7d wijziging
+16.9 pts
Marktdata
Bijgewerkt 1 uur geleden
Vertraagd15 mrt 24, 21:17 UTC2 dec 26, 07:59 UTC
Trends
Gerelateerde Markten
Gerelateerde vragen voor context, geen vergelijking van gelijkwaardige contracten.
What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold MarketsWill molecular jackhammers have at least 50% tumour-free efficacy in Phase 2 clinical trials?
Manifold MarketsHow many tuberculosis cases will be reported in the United States in 2026?
KalshiHow many human H5N1 cases will be reported in the United States in 2026?
KalshiHow many gonorrhea cases will be reported in the United States in 2026?
KalshiHow many human screwworm cases will be reported in the United States in 2026?
KalshiRegels
The 12 month phase 3 data indicates 75% vaccine efficacy of R21 in annual malaria sites in children at 12 months after the first dose was delivered.
- Phase 2b data at a 42 month timepoint showed 71% efficacy after four total doses (Abstract here, #6949).
- Resolves upon publication of peer-reviewed data from the R21 team at Oxford (expected to be before September 1st, 2025).
- Vaccine efficacy is defined as the primary endpoint for time to clinical malaria in seasonal sites, as defined in the paper linked above.
- 1Day Sooner has an R21 Status Report available here that may be useful.
- More malaria-related questions can be found on our Manifold account here.
